Saturday 17 October 2026
Export ATEC’s income statement to Excel — free account
Alphatec Holdings, Inc.
ATEC Healthcare Medical Devices
Alphatec Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $764.2 million, up 25.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.1%, EPS grew 40.7%, free cash flow fell 146.9% and total debt fell 7.79%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.45
0.48
−4.39%
Follow ATEC
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 1.80 | 1.58 | 2.02 | 1.18 | 2.19 | 10.31 | 5.73 | 8.66 | 4.88 | 8.81 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 9.65 | 5.80 | 4.21 | 7.75 | 14.97 | 19.36 | 13.65 | 19.14 | 17.34 | 22.66 | |||||
| People | |||||||||||||||
| People | Employees | 162 | 138 | 195 | 227 | 296 | 561 | 705 | 839 | 867 | 913 | ||||
| Revenue/emp, $m | 0.74 | 0.74 | 0.47 | 0.50 | 0.49 | 0.43 | 0.50 | 0.57 | 0.71 | 0.84 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 120 | 102 | 92 | 113 | 145 | 243 | 351 | 482 | 612 | 764 | ||||
| Gross margin, % | 63.31 | 67.06 | 68.97 | 68.41 | 70.76 | 64.87 | 66.42 | 61.36 | 66.72 | 67.63 | |||||
| EBT | (31) | (5) | (30) | (57) | (79) | (144) | (152) | (187) | (162) | (143) | |||||
| EBT margin, % | (25.73) | (4.50) | (32.90) | (50.38) | (54.43) | (59.27) | (43.32) | (38.76) | (26.50) | (18.77) | |||||
| Net income | (30) | (2) | (29) | (57) | (79) | (143) | (151) | (187) | (162) | (143) | |||||
| Depreciation | 15 | 7 | 7 | 9 | 12 | 32 | 46 | 63 | 88 | 105 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 14.01 | 7.96 | 2.60 | 2.17 | 2.16 | 2.53 | 3.39 | 3.98 | 4.28 | 5.09 | ||||
| Earnings | (3.57) | (0.18) | (1.20) | (1.09) | (1.18) | (1.50) | (1.47) | (1.54) | (1.13) | (0.96) | |||||
| Cash flow | (1.16) | (0.68) | (0.73) | (0.63) | (0.69) | (0.76) | (0.73) | (0.65) | (0.31) | 0.30 | |||||
| Capex | (0.91) | (0.51) | (0.17) | (0.25) | (0.36) | (0.71) | (0.56) | (0.72) | (0.65) | (0.33) | |||||
| Free cash flow | (2.07) | (1.19) | (0.90) | (0.88) | (1.05) | (1.47) | (1.29) | (1.36) | (0.96) | (0.03) | |||||
| Book value | (4.84) | (2.08) | 0.50 | 0.84 | 1.94 | 0.83 | (0.34) | 0.64 | (0.10) | 0.08 | |||||
| Shares, m | 9 | 13 | 35 | 52 | 67 | 96 | 103 | 121 | 143 | 150 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | 0.23 | 0.34 | 0.88 | 3.27 | 6.72 | 4.52 | 3.49 | 3.73 | 2.15 | 4.13 | |||||
| P/B | 0.00 | 0.00 | 4.60 | 8.50 | 7.49 | 13.84 | 0.00 | 23.05 | 0.00 | 254.09 | |||||
| EV/Sales | 0.45 | 0.52 | 1.06 | 3.33 | 6.27 | 5.11 | 4.30 | 4.34 | 2.86 | 4.66 | |||||
| EV/FCF | (2.97) | (3.30) | (2.99) | (8.05) | (12.84) | (8.70) | (11.30) | (12.65) | (12.70) | (807.85) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (10) | (9) | (26) | (33) | (46) | (73) | (75) | (78) | (45) | 45 | ||||
| Capex | (8) | (6) | (6) | (13) | (24) | (69) | (58) | (87) | (93) | (50) | |||||
| Free cash flow | (18) | (15) | (32) | (46) | (70) | (142) | (133) | (165) | (138) | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 33 | 37 | 45 | 72 | 126 | 230 | 117 | 294 | 264 | 232 | ||||
| Total debt | 46 | 41 | 46 | 54 | 43 | 331 | 369 | 513 | 576 | 501 | |||||
| Net debt | 27 | 19 | 17 | 7 | (65) | 144 | 285 | 292 | 437 | 341 | |||||
| Shareholders’ equity | (42) | (27) | 18 | 44 | 130 | 79 | (35) | 78 | (14) | 12 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (24.88) | (2.57) | (39.66) | (38.07) | (36.64) | (34.33) | (27.68) | (28.15) | (20.51) | (18.30) | ||||
| ROIC | 0.00 | 0.00 | (41.14) | (58.56) | (56.43) | (35.86) | (36.75) | (29.29) | (20.11) | (14.54) | |||||
| ROE | 76.65 | 6.73 | 934.91 | (186.27) | (91.05) | (136.68) | (676.09) | (859.11) | (507.05) | 16,450.51 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Alphatec Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| UFPT UFP Technologies, Inc. | $2.3B | 31.2× | 23.6× | +15.07% (above 0%: growing) | +20.63% (above 0%: growing) | −35.77% (below 0%: shrinking) | 29.27% | 16.15% | Compare |
| BFLY Butterfly Network, Inc. | $2.1B | — (loss-making) | — (loss-making) | +39.47% (above 0%: growing) | n/m | −113.85% (below 0%: shrinking) | 71.41% | (41.90%) | Compare |
| AXGN AxoGen, Inc. | $2.1B | — (loss-making) | — (loss-making) | +23.06% (above 0%: growing) | n/m | −17.36% (below 0%: shrinking) | 72.67% | (3.09%) | Compare |
| INSP Inspire Medical Systems, Inc. | $2.0B | 14.8× | 93.5× | −7.60% (below 0%: shrinking) | n/m | +322.84% (above 0%: growing) | 85.48% | (0.26%) | Compare |
| ESTA Establishment Labs Holdings Inc. | $1.8B | — (loss-making) | — (loss-making) | +31.66% (above 0%: growing) | n/m | +2.75% (above 0%: growing) | 70.64% | (6.35%) | Compare |
| ATEC Alphatec Holdings, Inc. | $1.7B | — (loss-making) | — (loss-making) | +15.07% (above 0%: growing) | n/m | −146.87% (below 0%: shrinking) | 72.17% | (0.89%) | |
| NVCR NovoCure Limited | $1.7B | — (loss-making) | — (loss-making) | +15.60% (above 0%: growing) | n/m | +105.68% (above 0%: growing) | 77.61% | (5.75%) | Compare |
| CNMD CONMED Corporation | $1.4B | 25.3× | 8.8× | +0.33% (above 0%: growing) | +11.59% (above 0%: growing) | +45.96% (above 0%: growing) | 57.49% | 10.60% | Compare |
| BVS Bioventus Inc. | $1.2B | 16.4× | 21.4× | +3.76% (above 0%: growing) | +345.45% (above 0%: growing) | −25.11% (below 0%: shrinking) | 68.97% | 12.48% | Compare |
| Median of peers | $1.9B | 20.8× | 22.5× | +15.34% | +20.63% | −7.30% | 71.03% | (1.67%) |
Alphatec Holdings, Inc. (ATEC) key facts
- Strength: Alphatec Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $764.2 million, up 25.0% from fiscal 2024.
- Alphatec Holdings, Inc. (ATEC) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ATEC traded at $10.45, a market capitalization of $1.7 billion.
- Return on equity was 16,450.5% and debt-to-equity -42.32.
- Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.89 (distress zone) for fiscal 2025.